The medication plays a role in managing discomfort and symptoms related to inflammatory or irritative states. Catafly is applied across domains where additional symptomatic support is needed, commonly used to help with symptoms related to physical discomfort and systemic imbalance.

---

Easing Symptoms and Supporting Daily Comfort

Catafly is considered relevant when symptoms intensify and supportive relief is needed. It is commonly used across conditions presenting with acute episodes or fluctuating manifestations, such as symptoms related to inflammation, physical discomfort, and specific types of body aches. It is applied when appropriate for symptoms that create noticeable physiological strain or interfere with daily comfort. The medication supports the patient during difficult episodes by easing distress and is relevant when short-term symptomatic assistance is needed.

---

Quick Facts

• Therapeutic Domain: Used in situations involving certain distressing symptoms.
• Symptom Management: Helps address symptom clusters that may become intense or disruptive.
• Clinical Context: Applied in clinical settings that involve acute or unstable symptom patterns.

Regulatory References

1. NIH DailyMed official labeling

Official Population Eligibility for Catafly

Catafly (Diclofenac Potassium) is authorized for use primarily in adults 18 years of age and older. Use in children under 14 years is generally not recommended.

Eligibility Category	Status as per Regulatory Labeling
Absolute Contraindications	Must not use if there is known hypersensitivity to diclofenac or other NSAIDs (e.g., aspirin-induced asthma, urticaria).
Cardiovascular Status	Contraindicated in the setting of coronary artery bypass graft (CABG) surgery, established congestive heart failure (NYHA Class II-IV), and established ischemic heart disease or cerebrovascular disease.
Gastrointestinal Risk	Contraindicated with active peptic ulceration, gastrointestinal bleeding, or a history of recurrent ulcer/hemorrhage.
Organ Function	Contraindicated in patients with severe renal or severe hepatic impairment.
Pregnancy	Contraindicated at 30 weeks gestation and later (third trimester). Not recommended between 20 and 30 weeks gestation, or during the first and second trimesters unless essential.
Lactation	Not recommended due to excretion into breast milk.
Older Adults	Use requires caution and monitoring; the lowest effective dose should be used for the shortest duration due to increased risk of serious gastrointestinal events.

Regulatory documents define that patients free of these severe contraindications are eligible for use, while those with moderate organ impairment or cardiovascular risk factors are advised to use the medicine only under special consideration.

Official Interaction Classifications and Restrictions

Regulatory documents establish specific interaction patterns for Diclofenac Potassium, classifying combinations based on risk and documented pharmacokinetic/pharmacodynamic effects. Use is formally contraindicated for treating peri-operative pain in the setting of Coronary Artery Bypass Graft (CABG) surgery, and co-administration with other systemic NSAIDs or Aspirin is not generally recommended due to increased adverse event risk.

Substance Category	Official Interaction Outcome	Mechanistic Basis Cited
Anticoagulants/SSRIs/Corticosteroids	Increased risk of serious gastrointestinal bleeding.	Pharmacodynamic Risk Enhancement
ACE Inhibitors / ARBs / Diuretics	May diminish antihypertensive/diuretic effect; risk of renal function deterioration.	Pharmacodynamic Risk/Renal Effect
CYP2C9 Inhibitors (e.g., Voriconazole)	Significant increase in Diclofenac plasma levels (Cmax and AUC).	Pharmacokinetic Exposure Modification
Lithium / Methotrexate	Diclofenac reduces their renal clearance, leading to elevated plasma concentrations.	Transporter/Clearance Interference

For the granules for oral solution formulation, regulatory labeling specifies a timing-based rule that the medicine must be taken on an empty stomach as food reduces the rate of absorption. Caution is also advised when co-administering with alcohol due to increased risk of gastrointestinal bleeding. Furthermore, the official labeling notes that in elderly, volume-depleted, or renally impaired patients, co-use with antihypertensives or diuretics requires monitoring for potential renal function decline.

Centrality of Enzyme Inhibition in Eicosanoid Synthesis

The primary action of Catafly (Diclofenac Potassium) involves the reversible, competitive inhibition of the Cyclooxygenase ( COX) enzymes, mainly the inducible COX-2 isoform. This molecular interaction prevents the conversion of arachidonic acid into prostanoids like PGE2, which are central to mediating inflammatory responses.

---

Modulation of Peripheral Nociceptor Sensitization

By suppressing the synthesis of PGE2 at peripheral nerve endings, the drug directly reduces the amount of chemical mediators available to sensitize nociceptors (pain receptors). This physiological consequence limits the signaling cascade initiated by nociceptive afferents to the central nervous system, elevating the activation threshold of peripheral sensory afferents.

---

Regulation of Central Thermostat Function

The mechanism extends centrally to the hypothalamus, where the drug's action suppresses PGE2 synthesis in the brain. This targeted activity reverses the chemical signal that elevates the body’s thermal set point during states of pyrogen-induced signaling, enabling endogenous thermoregulatory processes.

Catafly (Diclofenac Potassium Granules for Oral Solution) is administered exclusively via the oral route, following specific instructions designed to support its intended rapid absorption profile. The use of this medicine is restricted to short-term management of acute symptoms, strictly adhering to the dosage limits and duration constraints established for this formulation.

Preparation and Administration

The medicine is supplied as granules and must be prepared immediately before ingestion. The granules are required to be dissolved in a small amount of water to create the oral solution before being taken. To facilitate its fast-acting nature, the medicine is typically taken before meals or on an empty stomach.

Dosing and Frequency

The standardized single adult dose of Catafly is 50 mg of Diclofenac Potassium. This dose may be repeated as necessary, up to a maximum frequency of three times a day. It is critical not to exceed the maximum recommended total daily dose of 150 mg. Treatment must be limited to the lowest effective dose for the shortest possible duration to manage symptoms.

Population-Based Use

Dosing for certain populations, such as older adults (geriatric patients) and those with known hepatic or renal impairment, should start at the lowest effective dose. This ensures controlled use within the standard administration protocol.

Research Evidence / Overview of Studies for Catafly

---

Evidence for Use in Acute Pain States

This section will summarize the structure of the clinical research base—primarily short-term Randomized Controlled Trials (RCTs) and systematic reviews—that examined the medicine's role in standardized acute pain models, such as pain following surgery or dental procedures.

The research exploring how symptoms change over time primarily consists of short-term randomized controlled trials and subsequent scientific reviews. These studies was studied for episodic symptom patterns, such as pain that occurs right after dental surgery or certain short-term musculoskeletal injuries. The outcomes monitored was observed in these studies included the time elapsed until the onset of analgesic action measurement and the duration of the analgesic action measurement (measured by the time until rescue medication was requested).

However, follow-up durations were limited in these efficacy trials, rarely extending beyond a short period like 12 hours. Consequently, long-term outcomes are not fully established, and there is limited information regarding extended dosing patterns.

---

Evidence for Use in Acute Migraine Attacks

This part outlines the studies, primarily pivotal efficacy trials, that investigated the use of the medicine for the intervention during a single, acute migraine episode, detailing the specific outcomes tracked by researchers, such as pain-free status.

Research for this indication was evaluated in randomized controlled trials focusing on adults managing a single, acute migraine episode. The outcomes monitored focused on episodic or acute changes, specifically tracking the proportion of participants who reported headache status at defined time points and whether their most bothersome associated symptoms was observed in the study period.

Research focuses exclusively on single-attack intervention during phases of heightened symptom activity. Therefore, long-term effects are not fully established, and data are still emerging regarding patterns of use over multiple recurrent episodes.

---

Research Gaps and Areas of Uncertainty

This final section clarifies the limitations documented within the research record, synthesizing the main evidence gaps, inconsistent findings, and areas where future research is needed to fully characterize the medicine's performance.

The evidence helps show what has been observed so far, but several limitations restrict the certainty of the findings. For instance, the short-term nature of many efficacy trials means that follow-up durations were limited, leaving long-term effects not fully established. Furthermore, sample sizes were modest in some specific comparison studies, making subgroup findings uncertain or non-generalizable. Research provides context but not individual predictions, and findings describe group patterns, not personal outcomes.

Key Studies & References

1. Efficacy of ultramicronised diclofenac in patients with osteoarthritis – systematic review with network meta-analysis

Common questions about Catafly (FAQ)

Q: How quickly does Catafly start working?

A: Studies of this specific Diclofenac Potassium formulation indicate that the start of pain relief may be rapid. Official clinical pharmacology information indicates that analgesic action may begin as quickly as 30 minutes following administration.

Q: How long do the effects of Catafly last?

A: The required dosing frequency provides context on the duration of effect. Official product information notes that the medicine may be taken up to three times a day, which is consistent with a repeated dosing interval of approximately 6 to 8 hours.

Q: Are there different strengths or forms of Catafly available?

A: The formulation specifically known as Catafly is the 50 mg Diclofenac Potassium granule packet intended to be mixed into a solution. While other oral forms of the active ingredient Diclofenac exist (such as tablets), they are not necessarily interchangeable with this specific preparation.

Q: What happens if I miss a scheduled dose of Catafly?

A: Catafly is authorized for the short-term management of acute symptoms. If a dose is missed, patient counseling generally advises taking the next scheduled dose when it is needed, without taking an extra dose to make up for the one that was missed.

Q: What should I do if a side effect of Catafly seems serious?

A: Official patient information advises stopping the medicine immediately and seeking emergency medical help if signs of a serious reaction occur. These signs can include chest pain, shortness of breath, slurred speech, or sudden swelling of the face or throat.

Q: Is Catafly an antibiotic?

A: No. Catafly is chemically classified as a Non-Steroidal Anti-inflammatory Drug (NSAID). Its purpose is to relieve pain, inflammation, and fever, not to treat bacterial infections like an antibiotic.

Q: Is Catafly available over-the-counter?

A: No. The specific 50 mg Diclofenac Potassium granule formulation is not an over-the-counter product. Regulatory labeling classifies this product as requiring a prescription.

Q: What is the difference between Catafly and plain Diclofenac?

A: Catafly is a brand name for a formulation that uses the Potassium salt of Diclofenac in a quick-dissolving granular form. This specific salt and preparation is designed for faster absorption compared to other standard oral Diclofenac formulations that may contain the Sodium salt.

Q: Can Catafly be used for nerve pain?

A: Regulatory documents list the medicine’s formal indications as including mild to moderate pain, osteoarthritis, rheumatoid arthritis, and primary dysmenorrhea. Pain specifically classified as 'nerve pain' (neuropathic pain) is not listed among the formal indications.

Q: Is Catafly a generic or a brand-name medication?

A: Catafly is the registered brand name for this particular formulation of Diclofenac Potassium. The active component, Diclofenac Potassium, is the generic ingredient.

Q: Do food or milk affect how Catafly works?

A: Official product information notes that taking this medicine with food may affect its action, as the product is intended to be taken on an empty stomach. This specific instruction supports the drug’s fast-acting nature.

Q: Does Catafly cause drowsiness, making it unsafe to drive?

A: Official product information notes that patients who experience certain side effects should use caution with activities that require alertness. If you experience reactions such as dizziness, somnolence (drowsiness), or blurred vision, you should avoid driving or operating machinery.

Q: Are there research studies comparing Catafly to other pain relievers?

A: Scientific literature includes systematic reviews and meta-analyses that have compared the overall efficacy and safety profile of the active ingredient, Diclofenac, to other common Non-Steroidal Anti-inflammatory Drugs (NSAIDs).

Q: Is there a maximum amount of time I should use Catafly consecutively?

A: Regulatory guidance emphasizes that the medicine should be used at the lowest effective dose for the shortest duration possible to manage acute symptoms. It is not intended for long-term or chronic use.

Q: Does the official product information mention anything about withdrawal effects from Catafly?

A: Official regulatory documentation covering drug dependence and abuse for this product does not contain any information regarding potential withdrawal effects upon discontinuing the medicine.

Q: Is Catafly a habit-forming or addictive drug?

A: No. Catafly is a Non-Steroidal Anti-inflammatory Drug (NSAID) and is not classified as a controlled substance. Official documentation does not indicate that this medicine carries a risk of being habit-forming or addictive.

Q: Is Catafly available as a liquid or syrup formulation?

A: The product is supplied as granules in an individual packet. These granules are formulated to be mixed with a small amount of water to create an oral solution immediately prior to being taken.

Q: Does the drug label mention any specific lifestyle changes needed while taking Catafly?

A: Official patient counseling focuses primarily on safety precautions. Key advice includes strictly avoiding alcohol due to the increased risk of serious gastrointestinal bleeding, and being vigilant for symptoms of serious cardiovascular events.

Q: What does official research say about Catafly's use for dental pain?

A: Clinical studies have specifically examined Diclofenac Potassium for use in managing pain experienced after dental procedures. This research supports its efficacy for pain control and highlights its rapid action in this setting.

Q: What is the recommended age limit for using Catafly?

A: The specific formulation is indicated for use in adults 18 years of age and older. Regulatory documents state that the safe and effective use of this product in patients younger than 18 years is not established.

Storage and Environmental Control

Catafly (diclofenac potassium) must be stored at Controlled Room Temperature, maintained between 20 C to 25 C (68 F to 77 F). The regulatory labeling permits brief temperature excursions up to 30 C. It is mandatory to keep the product from freezing and store it away from heat, moisture, and direct light.

Packaging and Child Safety

The container must be kept tightly closed when not in use. For the granular form, the individual packet must be opened immediately right before use. As a safety requirement, the medicine must be stored out of the reach of children.

Disposal Requirements

Unused or expired Catafly must be discarded according to local regulations for pharmaceutical waste. Disposal instructions emphasize preventing the product from entering drains, other waterways, or soil to avoid environmental release.